Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

80.25 +1.77 (+2.25%)
Delayed Quote Updated: 12:39 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Tempus Reports Third Quarter 2026 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Expands Strategic Collaboration with Bristol Myers Squibb
From Tempus AI, Inc.
Via Business Wire
News headline image
Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions
From Pathos AI
Via Business Wire
News headline image
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus to Report Third Quarter 2026 Financial Results on November 2
From Tempus AI, Inc.
Via Business Wire
News headline image
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034 New York, NY – October 15,... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034 
From FN Media
Via GlobeNewswire
News headline image
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases
From Ambry Genetics
Via Business Wire
News headline image
Tempus Announces Multi-Year Collaboration with Moderna and Merck
From Tempus
Via Business Wire
News headline image
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
From Tempus AI, Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
From Tempus AI, Inc.
Via Business Wire
News headline image
AI Found an Influenza Target That Survives Viral Mutation
Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT) 
From Equity Insider
Via GlobeNewswire
News headline image
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Reports Second Quarter 2026 Results
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
From Tempus AI, Inc
Via Business Wire
News headline image
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
From Tempus
Via Business Wire
News headline image
Tempus to Report Second Quarter 2026 Financial Results on July 30
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
From Tempus AI, Inc.
Via Business Wire
News headline image
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
From Ambry Genetics
Via Business Wire
News headline image
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
News headline image
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.